GeoVax Responds to WHO's Mpox Emergency Declaration with GEO-MVA Vaccine Candidate
GeoVax Labs, Inc. is actively addressing the Mpox epidemic with its GEO-MVA vaccine candidate in response to WHO's emergency declaration. Learn how GeoVax's innovative approach aims to bolster global vaccine supply and combat the growing public health crisis.
This news matters as the ongoing Mpox epidemic poses a severe global threat, highlighted by WHO's emergency declarations. GeoVax's development of GEO-MVA offers a potential solution to the critical vaccine supply crisis, aiming to enhance global preparedness and combat the escalating public health crisis effectively.
